Taste, Smell and Chemotherapy (TASTY)
NCT01641172 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140
Last updated 2024-04-19
Summary
Taste and smell abnormalities are common in cancer patients undergoing chemotherapy, with a prevalence ranging from 46% to 77% for taste changes, and 35% to 75% for smell changes. These chemosensory changes are distressing for patients and can lead to changes in appetite, food choice, and nutrient intake. These changes can result in malnutrition and weight loss. Possibly, also unhealthy eating patterns can be developed due to these taste and smell changes, given the high prevalence of obesity among survivors of certain cancer types. The primary objective is to investigate the nature, prevalence, and duration of taste and smell changes in patients with disseminated testicular cancer treated with cisplatin based chemotherapy.
Conditions
- Testicular Cancer
Interventions
- PROCEDURE
-
Dexa scan
the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study. The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.
- PROCEDURE
-
audiogram
the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study. The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.
- PROCEDURE
-
measurement of heart rate variability and baroreflex sensitivity
the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study. The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year.
- PROCEDURE
-
Glucose tolerance assessment
Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study. The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year.
- DIETARY_SUPPLEMENT
-
oral nutrition supplements
a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
- BEHAVIORAL
-
Two day food records
Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
- BEHAVIORAL
-
Food Frequency Questionnaire
A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
Sponsors & Collaborators
-
University Medical Center Groningen
lead OTHER
Principal Investigators
-
A KL Reyners, MD, PhD · University Medical Center Groningen
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2016-01-31
- Completion
- 2016-01-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
NCT03571126 ·Status: UNKNOWN ·Phase: PHASE4
-
Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer
NCT00070148 ·Status: COMPLETED ·Phase: PHASE3
-
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
NCT00880191 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting
NCT01993381 ·Status: UNKNOWN
-
Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer
NCT05244577 ·Status: UNKNOWN ·Phase: PHASE3
-
Treatment Algorithm for Nausea and Vomiting in the Palliative Phase
NCT03017391 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy
NCT04141514 ·Status: RECRUITING ·Phase: NA
-
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
NCT00343863 ·Status: COMPLETED ·Phase: NA
-
Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer
NCT00416689 ·Status: COMPLETED
-
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT07130617 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer
NCT04350229 ·Status: COMPLETED ·Phase: NA
-
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00553059 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
NCT02203253 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV
NCT04437017 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
NCT01012336 ·Status: COMPLETED ·Phase: PHASE2
-
Study of HR20013 for Injection in Patients With Malignant Solid Tumors
NCT05465681 ·Status: COMPLETED ·Phase: PHASE1
-
Can Fasting Decrease the Side Effects of Chemotherapy?
NCT04027478 ·Status: UNKNOWN ·Phase: NA
-
Chemoradiation-Induced Nausea and Emesis: Quality of Life
NCT00394602 ·Status: TERMINATED
-
Prevalence of Delayed Chemotherapy Associated Nausea
NCT04342780 ·Status: COMPLETED
-
Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy
NCT04785495 ·Status: UNKNOWN
-
Observational Study of Delayed Nausea and Vomiting
NCT00696280 ·Status: COMPLETED
-
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT04430361 ·Status: UNKNOWN ·Phase: PHASE2
-
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
NCT03079219 ·Status: COMPLETED ·Phase: PHASE3
-
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
NCT00104403 ·Status: COMPLETED ·Phase: PHASE2
-
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
NCT01640340 ·Status: COMPLETED ·Phase: NA